6960 Results (Page 7 of 279)
Pharmaceuticals Markets Research Reports
UK Atopic Dermatitis Therapeutics Market Analysis
The UK Atopic Dermatitis Therapeutics Market was valued at US $320 Mn in 2022, and is predicted to grow at (CAGR) of 6.8% from 2023 to 2030, to US $541 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), evolving treatment landscape of the industry, and high medical unmet needs and diagnoses. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Galderma, AbbVie, Anacor, Meda, and Allergan, among others.
UAE Atopic Dermatitis Therapeutics Market Analysis
The UAE Atopic Dermatitis Therapeutics Market was valued at US $62 Mn in 2022, and is predicted to grow at (CAGR) of 9.8% from 2023 to 2030, to US $130 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies, and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, and Merck, among others.
Spain Atopic Dermatitis Therapeutics Market Analysis
The Spain Atopic Dermatitis Therapeutics Market was valued at US $237 Mn in 2022, and is predicted to grow at (CAGR) of 7.8% from 2023 to 2030, to US $433 Mn by 2030. The key drivers of this industry include a surge in the prevalence of Atopic Dermatitis (AD), increased awareness and diagnosis, and lifestyle modifications. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Bayer, AbbVie, Viatris, Leo Pharma, and Regeneron, among others.
South Africa Atopic Dermatitis Therapeutics Market Analysis
The South Africa Atopic Dermatitis Therapeutics Market was valued at US $80 Mn in 2022, and is predicted to grow at (CAGR) of 10.03% from 2023 to 2030, to US $172 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), increasing government initiatives, and untapped market potential. The industry is primarily dominated by players such as Sanofi, Pfizer, Regeneron, Astellas, Novartis, Meda, and Allergan, among others.
Singapore Atopic Dermatitis Therapeutics Market Analysis
The Singapore Atopic Dermatitis Therapeutics Market was valued at US $15 Mn in 2022, and is predicted to grow at (CAGR) of 9.4% from 2023 to 2030, to US $30 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), strong healthcare infrastructure, supportive government policies, and others. The industry is primarily dominated by players such as Sanofi, Galderma, Merck, AbbVie, Glenmark, Novartis, and Johnson & Johnson, among others.
Saudi Arabia Atopic Dermatitis Therapeutics Market Analysis
The Saudi Arabia Atopic Dermatitis Therapeutics Market was valued at US $209 Mn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $458 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), innovative drugs in the pipeline and evolving healthcare landscape. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Regeneron, Eli Lilly, and Astellas, among others.
Philippines Atopic Dermatitis Therapeutics Market Analysis
The Philippines Atopic Dermatitis Therapeutics Market was valued at US $27 Mn in 2022, and is predicted to grow at (CAGR) of 9.3% from 2023 to 2030, to US $55 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), supportive government policies and improved socioeconomic conditions. The industry is primarily dominated by players such as UniLab, Pascual, Merck, Abbott, Bayer, Novartis, Johnson & Johnson, among others.
Mexico Atopic Dermatitis Therapeutics Market Analysis
The Mexico Atopic Dermatitis Therapeutics Market was valued at US $185 Mn in 2022, and is predicted to grow at (CAGR) of 9.05% from 2023 to 2030, to US $369 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, Merck among others.
Malaysia Atopic Dermatitis Therapeutics Market Analysis
The Malaysia Atopic Dermatitis Therapeutics Market was valued at US $20 Mn in 2022, and is predicted to grow at (CAGR) of 9% from 2023 to 2030, to US $39 Mn by 2030. The key drivers of this industry include increasing disease burden of Atopic Dermatitis (AD), supportive government policies, and technological advancements. The industry is primarily dominated by players such as Meda, Ivax, Pharmaniaga, Marufa, Sanofi, Novartis, Johnson & Johnson, and AbbVie among others.
Kenya Atopic Dermatitis Therapeutics Market Analysis
The Kenya Atopic Dermatitis Therapeutics Market was valued at US $9 Mn in 2022, and is predicted to grow at (CAGR) of 9.9% from 2023 to 2030, to US $18 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), emergence of novel therapeutic options, and others. The industry is primarily dominated by players such as Sanofi, Pfizer, AbbVie, Astellas, Novartis, Eli Lilly, Galderma, and Leo Pharma, among others.
Japan Atopic Dermatitis Therapeutics Market Analysis
The Japan Atopic Dermatitis Therapeutics Market was valued at US $77 Mn in 2022, and is predicted to grow at (CAGR) of 9.3% from 2023 to 2030, to US $1.56 Bn by 2030. The key drivers of this industry include the increasing disease burden of Atopic Dermatitis (AD), growing healthcare spending, and an evolving treatment landscape. The industry is primarily dominated by players such as Otsuka, Maruho, Tanabe, Fuji Film, Sanofi, Novartis, Mitsubishi, and AbbVie, among others.
Indonesia Atopic Dermatitis Therapeutics Market Analysis
The Indonesia Atopic Dermatitis Therapeutics Market was valued at US $74 Mn in 2022, and is predicted to grow at (CAGR) of 8.8% from 2023 to 2030, to US $145 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), growing disposable income and improved healthcare infrastructure. The industry is primarily dominated by players such as Sanofi, Novartis, Abbott, Merck, Roche, GSK, Bristol-Myers Squibb, among others.
Germany Atopic Dermatitis Therapeutics Market Analysis
The Germany Atopic Dermatitis Therapeutics Market was valued at US US $450 in 2022, and is predicted to grow at (CAGR) of 7.8% from 2023 to 2030, to US $773 Mn by 2030. The key drivers of this industry include the surge in prevalence of Atopic Dermatitis (AD), increased awareness and diagnosis and lifestyle modifications. The industry is primarily dominated by players such as Pfizer, Astellas, Novartis, Bayer, AbbVie, Viatris, Leo Pharma, and Regeneron, among others.
France Atopic Dermatitis Therapeutics Market Analysis
The France Atopic Dermatitis Therapeutics Market was valued at US $388 Mn in 2022, and is predicted to grow at (CAGR) of 7.80% from 2023 to 2030, to US $617 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), emerging innovative therapeutics, and improved reimbursement policies. The industry is primarily dominated by players such as Sanofi, AbbVie, Viatris, Almirall, Leo Pharma, and Eli Lilly among others
Egypt Atopic Dermatitis Therapeutics Market Analysis
The Egypt Atopic Dermatitis Therapeutics Market was valued at US $34 Mn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $75 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), improving healthcare infrastructure, adverse environmental conditions, and others. The industry is primarily dominated by players such as Sanofi, Pfizer, AstraZeneca, Abbott, Novartis, and Johnson & Johnson, among others.
China Atopic Dermatitis Therapeutics Market Analysis
The China Atopic Dermatitis Therapeutics Market was valued at US $0.99 Bn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $2.16 Bn by 2030. The key drivers of this industry include a surge in the prevalence of Atopic Dermatitis (AD), emerging innovative therapeutics and increased awareness. The industry is primarily dominated by players such as Pfizer, Sanofi, Novartis, Galderma, AbbVie, Viatris, Bayer, and AstraZeneca, among others.
Canada Atopic Dermatitis Therapeutics Market Analysis
The Canada Atopic Dermatitis Therapeutics Market was valued at US $0.984 Bn in 2022, and is predicted to grow at (CAGR) of 8.8% from 2023 to 2030, to US $1.93 Bn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), expansion in healthcare coverage and supportive government initiatives. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Leo Pharma, Novartis among others.
Brazil Atopic Dermatitis Therapeutics Market Analysis
The Brazil Atopic Dermatitis Therapeutics Market was valued at US $308 Mn in 2022, and is predicted to grow at (CAGR) of 9.8% from 2023 to 2030, to US $650 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, Merck among others.
Vietnam Atherosclerosis Therapeutics Market Analysis
Vietnam Atherosclerosis Therapeutics Market was valued at $14 Mn in 2022 and is estimated to reach $22 Mn in 2030, exhibiting a CAGR of 5.93% during the forecast period. The rising prevalence of cardiovascular diseases, exacerbated by unhealthy dietary patterns, sedentary lifestyles, and a growing aging population worldwide, is anticipated to increase the need for atherosclerosis therapeutics. Leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Eli Lilly, Roche, Teva Pharmaceutical and Johnson & Johnson.
US Atherosclerosis Therapeutics Market Analysis
US Atherosclerosis Therapeutics Market was valued at $1176 Mn in 2022 and is estimated to reach $1573 Mn in 2030, exhibiting a CAGR of 3.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the increased incidence of sedentary behaviour, poor diets, and the aging of the world's population, which are all contributing factors to the prevalence of cardiovascular diseases. Top leading pharmaceutical companies currently operating in the market are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Johnson & Johnson, Eli Lilly, AbbVie, Roche and Amgen.
UK Atherosclerosis Therapeutics Market Analysis
UK Atherosclerosis Therapeutics Market was valued at $73 Mn in 2022 and is estimated to reach $97 Mn in 2030, exhibiting a CAGR of 3.7% during the forecast period. The market for atherosclerosis therapeutics is expected to rise as a result of the increasing prevalence of cardiovascular illnesses that have been exacerbated by unhealthy eating habits, sedentary lifestyles, and an aging population worldwide. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Merck & Co., Janssen Pharmaceuticals, Bayer, Abbott, Eli Lilly and Roche.
UAE Atherosclerosis Therapeutics Market Analysis
UAE Atherosclerosis Therapeutics Market was valued at $14 Mn in 2022 and is estimated to reach $24 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the growing incidence of cardiovascular diseases, which are being exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The leading pharmaceutical companies presently operating in the market are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Johnson & Johnson, Teva Pharmaceutical, Roche and Merck & Co.
Spain Atherosclerosis Therapeutics Market Analysis
Spain Atherosclerosis Therapeutics Market was valued at $54 Mn in 2022 and is estimated to reach $78 Mn in 2030, exhibiting a CAGR of 4.7% during the forecast period. The increasing prevalence of cardiovascular diseases, which are worsened by sedentary lifestyles, poor diets, and an aging global population, is expected to drive growth in the market for atherosclerosis treatments. Sanofi, Novartis, Pfizer, Bayer, AstraZeneca, AbbVie, Roche, Johnson & Johnson, and Bristol-Myers Squibb are well-known pharmaceutical companies that currently have a sizable share in the industry.
South Africa Atherosclerosis Therapeutics Market Analysis
South Africa Atherosclerosis Therapeutics Market was valued at $18 Mn in 2022 and is estimated to reach $31 Mn in 2030, exhibiting a CAGR of 6.93% during the forecast period. The increasing prevalence of cardiovascular diseases, aggravated by unhealthy dietary patterns, sedentary lifestyles, and a growing aging population worldwide, is anticipated to increase the need for atherosclerosis therapeutics. Leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, Sanofi, AstraZeneca, Merck Sharp & Dohme, Bayer, Johnson & Johnson, Aspen Pharmacare, Cipla Medpro and Adcock Ingram.
Singapore Atherosclerosis Therapeutics Market Analysis
Singapore Atherosclerosis Therapeutics Market was valued at $3 Mn in 2022 and is estimated to reach $5 Mn in 2030, exhibiting a CAGR of 6.3% during the forecast period. The increasing number of cardiovascular disease cases, which are exacerbated by poor dietary habits, sedentary lifestyles, and an aging global population, is predicted to drive up demand for atherosclerosis treatments. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott Laboratories, Eli Lilly, Eisai, Takeda and Mitsubishi Tanabe Pharma Corporation.